Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

Thomas Elmer Witzig, Arturo Molina, Leo I. Gordon, Christos Emmanouilides, Russell J. Schilder, Ian W. Flinn, Mohamed Darif, Roger Macklis, Katie Vo, Gregory A. Wiseman

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

BACKGROUND. Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non-Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. METHODS. Data on patients with recurring NHL treated with yttrium Y 90 ibritumomab tiuxetan in 4 clinical trials were reviewed to identify patients with a long-term response, defined as a time to progression of 12 months or longer. RESULTS. Long-term responses were seen in 37% (78/211) of patients. At a median follow-up of 53.5 months (range, 12.7-88.9) the median duration of response was 28.1 months and the median time to progression was 29.3 months. A third of these patients had been treated with at least 3 previous therapies, and 37% of them had not responded to their last therapy. The findings in patients with follicular lymphoma (n = 59) were similar to those in the overall population of long-term responders. The estimated overall survival at 5 years was 53% for all patients treated with 90Y ibritumomab tiuxetan and 81% for long-term responders. CONCLUSIONS. A single dose of 90Y ibritumomab tiuxetan can produce durable responses and prolonged overall survival in a substantial number of patients in whom previous therapies have failed.

Original languageEnglish (US)
Pages (from-to)1804-1810
Number of pages7
JournalCancer
Volume109
Issue number9
DOIs
StatePublished - May 1 2007

Fingerprint

B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Radioimmunotherapy
Follicular Lymphoma
Survival
ibritumomab tiuxetan
Therapeutics
Monoclonal Antibodies
Clinical Trials
Population

Keywords

  • Y ibritumomab tiuxetan
  • Non-Hodgkin lymphoma (NHL)
  • Radioimmunotherapy
  • Time to progression (TTP)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Witzig, T. E., Molina, A., Gordon, L. I., Emmanouilides, C., Schilder, R. J., Flinn, I. W., ... Wiseman, G. A. (2007). Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer, 109(9), 1804-1810. https://doi.org/10.1002/cncr.22617

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. / Witzig, Thomas Elmer; Molina, Arturo; Gordon, Leo I.; Emmanouilides, Christos; Schilder, Russell J.; Flinn, Ian W.; Darif, Mohamed; Macklis, Roger; Vo, Katie; Wiseman, Gregory A.

In: Cancer, Vol. 109, No. 9, 01.05.2007, p. 1804-1810.

Research output: Contribution to journalArticle

Witzig, TE, Molina, A, Gordon, LI, Emmanouilides, C, Schilder, RJ, Flinn, IW, Darif, M, Macklis, R, Vo, K & Wiseman, GA 2007, 'Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan', Cancer, vol. 109, no. 9, pp. 1804-1810. https://doi.org/10.1002/cncr.22617
Witzig, Thomas Elmer ; Molina, Arturo ; Gordon, Leo I. ; Emmanouilides, Christos ; Schilder, Russell J. ; Flinn, Ian W. ; Darif, Mohamed ; Macklis, Roger ; Vo, Katie ; Wiseman, Gregory A. / Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. In: Cancer. 2007 ; Vol. 109, No. 9. pp. 1804-1810.
@article{6637c10a27f04e238bb1c460579eb753,
title = "Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan",
abstract = "BACKGROUND. Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non-Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. METHODS. Data on patients with recurring NHL treated with yttrium Y 90 ibritumomab tiuxetan in 4 clinical trials were reviewed to identify patients with a long-term response, defined as a time to progression of 12 months or longer. RESULTS. Long-term responses were seen in 37{\%} (78/211) of patients. At a median follow-up of 53.5 months (range, 12.7-88.9) the median duration of response was 28.1 months and the median time to progression was 29.3 months. A third of these patients had been treated with at least 3 previous therapies, and 37{\%} of them had not responded to their last therapy. The findings in patients with follicular lymphoma (n = 59) were similar to those in the overall population of long-term responders. The estimated overall survival at 5 years was 53{\%} for all patients treated with 90Y ibritumomab tiuxetan and 81{\%} for long-term responders. CONCLUSIONS. A single dose of 90Y ibritumomab tiuxetan can produce durable responses and prolonged overall survival in a substantial number of patients in whom previous therapies have failed.",
keywords = "Y ibritumomab tiuxetan, Non-Hodgkin lymphoma (NHL), Radioimmunotherapy, Time to progression (TTP)",
author = "Witzig, {Thomas Elmer} and Arturo Molina and Gordon, {Leo I.} and Christos Emmanouilides and Schilder, {Russell J.} and Flinn, {Ian W.} and Mohamed Darif and Roger Macklis and Katie Vo and Wiseman, {Gregory A.}",
year = "2007",
month = "5",
day = "1",
doi = "10.1002/cncr.22617",
language = "English (US)",
volume = "109",
pages = "1804--1810",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

AU - Witzig, Thomas Elmer

AU - Molina, Arturo

AU - Gordon, Leo I.

AU - Emmanouilides, Christos

AU - Schilder, Russell J.

AU - Flinn, Ian W.

AU - Darif, Mohamed

AU - Macklis, Roger

AU - Vo, Katie

AU - Wiseman, Gregory A.

PY - 2007/5/1

Y1 - 2007/5/1

N2 - BACKGROUND. Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non-Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. METHODS. Data on patients with recurring NHL treated with yttrium Y 90 ibritumomab tiuxetan in 4 clinical trials were reviewed to identify patients with a long-term response, defined as a time to progression of 12 months or longer. RESULTS. Long-term responses were seen in 37% (78/211) of patients. At a median follow-up of 53.5 months (range, 12.7-88.9) the median duration of response was 28.1 months and the median time to progression was 29.3 months. A third of these patients had been treated with at least 3 previous therapies, and 37% of them had not responded to their last therapy. The findings in patients with follicular lymphoma (n = 59) were similar to those in the overall population of long-term responders. The estimated overall survival at 5 years was 53% for all patients treated with 90Y ibritumomab tiuxetan and 81% for long-term responders. CONCLUSIONS. A single dose of 90Y ibritumomab tiuxetan can produce durable responses and prolonged overall survival in a substantial number of patients in whom previous therapies have failed.

AB - BACKGROUND. Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non-Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. METHODS. Data on patients with recurring NHL treated with yttrium Y 90 ibritumomab tiuxetan in 4 clinical trials were reviewed to identify patients with a long-term response, defined as a time to progression of 12 months or longer. RESULTS. Long-term responses were seen in 37% (78/211) of patients. At a median follow-up of 53.5 months (range, 12.7-88.9) the median duration of response was 28.1 months and the median time to progression was 29.3 months. A third of these patients had been treated with at least 3 previous therapies, and 37% of them had not responded to their last therapy. The findings in patients with follicular lymphoma (n = 59) were similar to those in the overall population of long-term responders. The estimated overall survival at 5 years was 53% for all patients treated with 90Y ibritumomab tiuxetan and 81% for long-term responders. CONCLUSIONS. A single dose of 90Y ibritumomab tiuxetan can produce durable responses and prolonged overall survival in a substantial number of patients in whom previous therapies have failed.

KW - Y ibritumomab tiuxetan

KW - Non-Hodgkin lymphoma (NHL)

KW - Radioimmunotherapy

KW - Time to progression (TTP)

UR - http://www.scopus.com/inward/record.url?scp=34247561116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247561116&partnerID=8YFLogxK

U2 - 10.1002/cncr.22617

DO - 10.1002/cncr.22617

M3 - Article

C2 - 17380530

AN - SCOPUS:34247561116

VL - 109

SP - 1804

EP - 1810

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -